Biodel Inc. - Biodel Corporation - Presentations & Publications

Presentations & Publications

This site contains forward-looking statements about our business, including the timing and results of our clinical trials, potential indications for our product candidates, development timelines and the future financial results. Biopharmaceutical development inherently involves significant risks and uncertainties, including the risks outlined under "Risk Factors" and elsewhere in our preliminary prospectus. Our actual results may differ materially from our expectations due to these risks and uncertainties, including our near term dependence on our lead product candidate, Linjeta™, and risks relating to regulatory approval, research and development, intellectual property protection and litigation, existing and future competition, industry environment, ability to raise sufficient capital and other matters. Biodel undertakes no duty or obligation to update any forward-looking statements contained in this site as a result of new information, future events or changes in Biodel´s expectations. Further information on the factors and risks that could affect Biodel´s business, financial condition, and results of operations are contained in Biodel´s public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

Although we have attempted to provide accurate information on our website, we assume no responsibility for the accuracy of the information. In particular, we may not update our website on a daily or other regular basis. As such, the information and materials contained on our website may be out of date or include omissions or other errors. We may change the information provided on our website at any time without notice. All information provided on our website is provided "AS IS" without warranty of any kind. Biodel its affiliates and collaborators disclaim all warranties, express or implied, including those of merchantability and fitness for a particular purpose.

Archived Presentations	Date	Size
Ultra-Rapid U-400 Concentrated Recombinant Human Insulin: Pharmacokinetic and Pharmacodynamic Profiles in Diabetic Swine	Mar 1, 2013	102.8 KB
BIO CEO & Investor Conference	February 11, 2013	515.8 KB
Biodel Analyst / Investor R&D Day	Oct 11, 2012	3.9 MB
Development of Ultra-Rapid-Acting Prandial Insulin Analogs Requires Chelation of Zinc Ions and Charge Masking to Increase the Rate of Subcutaneous Absorption	Oct 2, 2012	100.9 KB
Biodel Presentation at Wedbush PacGrow Lifesciences Management Access Conference		513.3 KB
Biodel Presentation at JMP Securities Healthcare Conference	Jul 13, 2012	510.9 KB
Biodel Corporate Presentation	June 2012	500.7 KB
Evaluations of Modified Ultra-Rapid-Acting Linjeta™ Formulations BIOD-105 and BIOD-107 in Patients with Type 1 Diabetes	Jun 11, 2012	362.3 KB
Pharmacokinetic and Pharmacodynamic Comparison of New Ultra-Rapid-Acting Insulin Formulations in Diabetic Miniature Swine	Jun 10, 2012	97.4 KB
Graphical Presentation of Phase 1 Clinical Trial Top-line Results of BIOD-123 and BIOD-125	Apr 24, 2012	826.3 KB
ROTH 24th Annual OC Growth Stock Conference	Mar 14, 2012	1.5 MB
JPMorgan Healthcare Conference January 12, 2012 - Slides	Jan 12, 2012	1.6 MB
Wedbush 2011 Life Sciences Conference	Aug 16, 2011	554.2 KB
Sublingual Administration of Ultra-rapid-acting Insulin: Proof of Concept	Jul 29, 2011	21.0 MB
Assessment of Long-Term Safety and Efficacy of Linjeta™ in Patients with Type1 Diabetes	Jun 25, 2011	180.1 KB
Assessment of Long-Term Safety and Efficacy of Linjeta™ in Patients with Type2 Diabetes	Jun 25, 2011	131.4 KB
Roth 23rd Annual OC Growth Stock Conference	Mar 16, 2011	554.5 KB
A New Formulation of Insulin Glargine with an Extended Release Profile	Nov 12, 2010	333.6 KB
A Stabilized Liquid Glucagon Formulation of Bi-hormonal Pump Use	Nov 12, 2010	326.2 KB
Smart Basal Insulin Formulation That Releases Insulin in Response to Changing Blood Glucose Concentrations	Nov 12, 2010	273.4 KB
Characterization of Pharmacokinetics and Toleration of Three Variant Formulations of Linjeta	Nov 12, 2010	394.7 KB
Pharmacokinetics of novel formulations of insulin analogs providing a more rapid onset of action in the diabetic swine model	Sep 23, 2010	625.2 KB
Biocompatibility of the ultra-rapid insulin VIAject® (Linjeta™) with continuous insulin infusion sets	Sep 23, 2010	1.9 MB
A novel pH-neutral formulation of the monomeric insulin VIAject® (Linjeta™) has a faster onset of action than insulin lispro	Sep 21, 2010	609.7 KB
Wedbush Securities Life Sciences Best Ideas MAC Conference Presentation	Aug 3, 2010	714.4 KB
"Smart" Basal Insulin Formulation That Releases Insulin in Response to Blood Glucose Concentrations of Diabetic Swine	Jul 12, 2010	868.0 KB
Effect of EDTA Concentration on Ultra-Rapid Action of VIAject® in Diabetic Miniature Swine	July 12, 2010	429.4 KB
Pharmacokinetics and Pharmacodynamics of a New Rapid Acting Insulin Formulation Vialog in the Diabetic Swine Model	Jun 26, 2010	112.8 KB
An Open-Label Multicenter Trial of VIAject Efficacy Analyses	Jun 26, 2010	166.8 KB
A Novel pH−Neutral Formulation of the Monomeric Insulin VIAject® Has a Faster Onset of Action than Insulin Lispro	Jun 26, 2010	432.1 KB
An Open-Label Multicenter Trial of VIAject vs. Regular Human Insulin in Patients with Type 2 Diabetes: Final Analyses	Jun 25, 2010	1.0 MB
Ultra-rapid acting insulin VIAject® is suitable for use in insulin pumps 45th Annual Meeting of the German Diabetes Society (Deutsche Diabetes-Gesellschaft – DDG) Stuttgart Germany	May 12, 2010	422.1 KB
Clinical Finding for Patients Treated with VIAject®, an Ultra-Rapid Acting Formulation of Recombinant Human Insulin	Feb 12, 2010	990.9 KB
Postprandial Vascular Effects of VIAject Compared With Insulin Lispro and Regular Human Insulin in Patients With Type 2 Diabetes	Jan 2010	301.7 KB
Corporate Presentation - January	Jan 14, 2010	1.2 MB
Influence of Insulin Kinetics on the Post Receptor Signal Transduction of insulin In Patients with Type 2 Diabetes	Sep 30, 2009	97.0 KB
Rapidity of Hexameric Dissociation of Various Prandial Insulin Formulations	Jun 8, 2009	1.0 MB
Postprandial Vascular Effects of VIAject™ compared with Insulin Lispro and Regular Human Insulin in Patients with Type 2 Diabetes Mellitus	Jun 8, 2009	99.7 KB
Corporate Presentation: January	Jan 15, 2009	2.2 MB
Diabetes Technologies Conference	Nov 15, 2008	453.5 KB
Natixis Bleichroeder Hidden Gems Conference	Oct 13, 2008	1.7 MB
European Association for the Study of Diabetes: Poster Presentation	Sep 9, 2008	802.8 KB
European Association for the Study of Diabetes: Conference Call Presentation		294.3 KB
BioCentury Future Leaders Conference	Mar 27, 2008	531.5 KB
26th Annual JPMorgan Healthcare Conference	Jan 7, 2008	717.1 KB

Archived Publications	Date	Size
Postprandial Vascular Effects of VIAject Compared With Insulin Lispro and Regular Human Insulin in Patients With Type 2 Diabetes	Jan 2010	301.7 KB
Mealtime Glycemic Control Comparing VIAjectTM to Lispro	Oct 25, 2007	358.4 KB
Pharmacokinetics and Pharmacodynamics of Insulin VIAjectTM, Insulin Lispro and Regular Human Insulin When Injected Subcutaneously Immediately Before a Meal in Patients with Type 1 Diabetes	Sep 18, 2007	1.1 MB
A Regular Human Insulin Formulation with a More Rapid Onset of Action than Rapid-Acting Insulin	Nov 2006	104.1 KB
Pharmacodynamic Properties of VIAject™: A Novel Rapid-Acting Regular Human Insulin	Nov 4, 2006	108.9 KB
A Regular Human Insulin Formulation with a More Rapid Onset of Action than Rapid-Acting Insulin Analogues	Nov 2006	9.4 KB
Viaject™ Insulin Has Faster Onset of Action and Less Intra-Individual Variability than Regular Human Insulin in Patients With Type 1 Diabetes	Aug 2006	59.7 KB
Pharmacodynamics of VIAject TM: A Novel Rapid Acting Regular Human Insulin	Jun 2006	173.3 KB
Pharmacodynamics, Pharmacokinetics and Variability of Viaject™; A Novel, Rapid-Acting Regular Human Insulin, Tested by the Glucose Clamp Technique in Patients with Type 1 Diabetes and Healthy Normals	2006	1.1 MB
Pharmacodynamics, Pharmacokinetics and Variability of Viaject™: A Novel, Rapid-Acting Regular Human Insulin, Tested by the Glucose Clamp Technique in Patients with Type 1 Diabetes and Healthy Normals	2006	28.5 KB
Viaject™ Insulin Has Faster Onset of Action and Less Intra-Individual Variability Than Regular Human Insulin in Patients With Type 1 Diabetes	2006	56.8 KB
Pharmacodynamic Properties of Viaject™: A Novel Rapid-Acting Regular Human Insulin	2006	120.4 KB
Viaject™ Insulin Has Faster Onset of Action and Less Intra-Individual Variability than Regular Human Insulin in Patients With Type 1 Diabetes	2006	10.0 KB
Pharmacodynamic Properties of Viaject™: A Novel Rapid-Acting Regular Human Insulin	2006	11.0 KB
Pharmacodynamic Properties of VIAject™: A Novel Rapid-Acting Regular Human Insulin	Nov 2005	108.9 KB
Viaject™ Insulin Has Faster Onset of Action and Less Intra-Individual Variability than Regular Human Insulin in Patients With Type 1 Diabetes	2005	59.1 KB

News & Events

Diabetes is a disease characterized by abnormally high levels of blood glucose and inadequate levels of insulin. Glucose is a simple sugar used by all the cells of the body to produce energy and support life.

Humans need a minimum level of glucose in their blood at all times to function and stay alive. Insulin is a peptide hormone naturally secreted by the pancreas to regulate the body's management of glucose.

When a healthy individual begins a meal, the pancreas releases a natural spike of insulin, called the first-phase insulin release, which is critical to the body's overall control of glucose.

Many patients with diabetes lack the first-phase insulin release and must treat themselves with daily meal-time insulin injections to avoid the negative effects of hyperglycemia and hypoglycemia.

Presentations & Publications